undamentalytics Newsletter
Sign in

Alaunos Therapeutics, Inc. cash flow statement

In fiscal 2025, Alaunos Therapeutics, Inc.'s operations generated −$2.9m of cash; it spent $98,000 on capital projects, leaving free cash flow of −$3.0m.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2011Dec 20112012Dec 20122016Dec 20162017Dec 20172018Dec 20182020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash from operations−39−79−58−55−49−57−61−29−30−5−3−3
Depreciation and amortisation010011332000
Stock-based pay3588871143011
Capital spending1211010300000
Free cash flow−40−80−59−55−50−67−65−29−30−5−3−3
Free cash flow after stock pay−43−85−67−64−57−74−76−33−33−5−4−4
Share buybacks01002—000———
Shares issued———47——01500——

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: CELZ vs TCRTLYEL vs TCRTAIM vs TCRT

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Alaunos Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Alaunos Therapeutics, Inc.